Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it. Methods: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus. Results: PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration. Conclusions: Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve special consideration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,040
A Group Process Model for Problem Identification and Program Planning
Delbecq, A. L., & Van de Ven, A. H. (1971) · The Journal of Applied Behavioral Science · doi:10.1177/002188637100700404 · Cited by 1,145 · cited 1×
“A modified nominal group technique was used to reach consensus statements on PSMA PET/CT response assessment criteria [6, 7].”
MethodGuckenberger, M., Lievens, Y., Bouma, A. B., Collette, L., Dekker, A., deSouza, N. M., Dingemans, A.-M. C., Fournier, B., Hurkmans, C., Lecouvet, F. E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30718-1 · Cited by 1,111 · cited 1×
“All consensus statements were developed following the European Society for Radiotherapy and Oncology (ESRO) and European Organisation for Research and Treatment of Cancer (EORTC) consensus recommendations for classification of oligometastatic disease [10].”
Nominal group technique: An effective method for obtaining group consensus
Harvey, N., & Holmes, C. A. (2012) · International Journal of Nursing Practice · doi:10.1111/j.1440-172x.2012.02017.x · Cited by 808 · cited 1×
“A modified nominal group technique was used to reach consensus statements on PSMA PET/CT response assessment criteria [6, 7].”
Method68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Ceci, F., Cho, S., Giesel, F., Haberkorn, U., Hope, T. A., Kopka, K., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3670-z · Cited by 750 · cited 9×
“The one-day EAU/EANM PSMA PET/CT Response Assessment Criteria meeting received an unrestricted grant from Janssen, and no influences on the content of the meeting or on the publication.”
BackgroundMethodInfluentialSelf-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationEiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626
Self-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.012 · Cited by 389
Self-citationViolet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
Emmett, L., Yin, C., Crumbaker, M., Hruby, G., Kneebone, A., Epstein, R., Nguyen, Q., Hickey, A., Ihsheish, N., O’Neill, G., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223099 · Cited by 223
PSMA Ligands for PET Imaging of Prostate Cancer
Schwarzenboeck, S. M., Rauscher, I., Bluemel, C., Fendler, W. P., Rowe, S. P., Pomper, M. G., Asfhar-Oromieh, A., Herrmann, K., & Eiber, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191031 · Cited by 215 · cited 1×
“Different PSMA tracers, including [(68)Ga]Ga-PSMA-11 and [(18)F]F-labeled PSMA-1007 and [(18)F]DCFPyL tracers, are supposed to perform similarly, even if there is lack of comparative data [26].”
BackgroundSelf-citationRowe, S. P., Pienta, K. J., Pomper, M. G., & Gorin, M. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195255 · Cited by 170
Pinker, K., Riedl, C., & Weber, W. A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3687-3 · Cited by 169
Fanti, S., Hadaschik, B., & Herrmann, K. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233817 · Cited by 165
Self-citationFerdinandus, J., Violet, J., Sandhu, S., Hicks, R. J., Ravi Kumar, A. S., Iravani, A., Kong, G., Akhurst, T., Thang, S. P., Murphy, D. G., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04723-z · Cited by 164 · cited 1×
“Lutetium PSMA, due to its theranostic nature, is the only treatment where PSMA PET/CT has been used more frequently to evaluate response to therapy [27, 28].”
BackgroundAfshar-Oromieh, A., Debus, N., Uhrig, M., Hope, T. A., Evans, M. J., Holland-Letz, T., Giesel, F. L., Kopka, K., Hadaschik, B., Kratochwil, C., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4079-z · Cited by 162
Self-citationSeitz, A. K., Rauscher, I., Haller, B., Kroenke, M., Luther, S., Heck, M. M., Horn, T. D., Gschwend, J. E., Schwaiger, M., Eiber, M. J., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3887-x · Cited by 152
Self-citationGrubmüller, B., Senn, D., Kramer, G., Baltzer, P., D’Andrea, D., Grubmüller, K. H., Mitterhauser, M., Eidherr, H., Haug, A. R., Wadsak, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4236-4 · Cited by 148
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
Hope, T. A., Aggarwal, R. R., Chee, B. H., Tao, D. H., Greene, K. L., Cooperberg, M. R., Feng, F. Y.-C., Chang, A. J., Ryan, C. J., Small, E. J., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.192476 · Cited by 143
Aggarwal, R. R., Wei, X. X., Kim, W. B., Small, E. J., Ryan, C. J., Carroll, P. R., Cooperberg, M. R., Evans, M. J., & Hope, T. A. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.03.010 · Cited by 129
Consensus on molecular imaging and theranostics in prostate cancer
Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrió, I., Chiti, A., Clarke, N. W., Eiber, M., Bono, J. S. D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30604-1 · Cited by 124 · cited 1×
“Lutetium PSMA, due to its theranostic nature, is the only treatment where PSMA PET/CT has been used more frequently to evaluate response to therapy [27, 28].”
BackgroundSelf-citationHofman, M. S., Murphy, D. G., Williams, S. G., Nzenza, T., Herschtal, A., Lourenco, R. D. A., Bailey, D. L., Budd, R., Hicks, R. J., Francis, R. J., et al. (2018) · BJU International · doi:10.1111/bju.14374 · Cited by 121 · cited 2×
“PSMA PET/CT is considered a potentially useful tool for evaluating responses to therapy, but there is lack of data regarding criteria to be used for evaluating PSMA PET/CT findings in relation to therapy response assessment [2, 4].”
MethodResultÖnal, C., Güler, O. C., Torun, N., Reyhan, M., & Yapar, A. F. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04581-4 · Cited by 45 · cited 4×
“Asking whether PSMA PET/CT can be used before, after, and during treatment is an important question, because there are, for example, concerns regarding how to interpret uptake of tracer especially in hormone-naive patients starting androgen deprivation therapy (ADT) [11].”
BackgroundInfluentialRepeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer
Jansen, B. H. E., Cysouw, M. C. F., Vis, A. N., van Moorselaar, R. J. A., Voortman, J., Bodar, Y. J. L., Schober, P. R., Hendrikse, N. H., Hoekstra, O. S., Boellaard, R., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236075 · Cited by 35
Self-citationQuantitative Test–Retest Measurement of 68Ga-PSMA-HBED-CC in Tumor and Normal Tissue
Pollard, J. H., Raman, C., Zakharia, Y., Tracy, C. R., Nepple, K. G., Ginader, T., Breheny, P. J., & Sunderland, J. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236083 · Cited by 32
Gupta, M., Choudhury, P., Rawal, S. K., Goel, H. C., & Rao, S. (2019) · Urology Annals · doi:10.4103/ua.ua_111_18 · Cited by 17
Zukotynski, K., Valliant, J. F., Bénard, F., Rowe, S. P., Kim, C. K., Pomper, M. G., & Cho, S. Y. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001966 · Cited by 16
Cited by
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Ceci, F., Oprea-Lager, D. E., Emmett, L., Adam, J. A., Bomanji, J., Czernin, J., Eiber, M., Haberkorn, U., Hofman, M. S., Hope, T. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05245-y · Cited by 368
Self-citationSathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263618 · Cited by 81
“We used PSMA PET/CT criteria to categorize patients as responders or nonresponders.”
BackgroundInfluentialImaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Fanti, S., Goffin, K., Hadaschik, B. A., Herrmann, K., Maurer, T., MacLennan, S., Oprea-Lager, D. E., Oyen, W. J., Rouvière, O., Mottet, N., & Bjartell, A.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2020-07-02
- Volume
- 48
- Issue
- 2
- Pages
- 469-476
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3040491196
- Cited by
- 214
- References
- 27
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.